Patrick James Heron
Independent DirectorMr. Patrick James Heron, M.B.A. serves as Managing Partner of Frazier Management, L.L.C. He served as Director at Imago BioSciences, Inc. until 2022. He serves as Independent Director at MBX Biosciences, Inc. since July 2020. He joined the Frazier Management, L.L.C. in May 1999. He also serves as Managing Partner at Frazier Life Sciences Management, LP. He is Member of the Advisory Board of Tubulis GmbH (formerly known as Tubulis Technologies). He was Managing General Partner of Frazier Management, L.L.C. from 2005. He co-leads Frazier Life Sciences team and invests across the spectrum of therapeutics opportunities, from early-stage drug development companies to commercial-stage pharmaceutical companies. He has been Lead Independent Director and had been an Independent Director at HilleVax, Inc since March 2020. He served as the Director of Imago BioSciences, Inc. since October 2014 until June 1, 2022. He had been the Independent Chairman at Arcutis Biotherapeutics, Inc. since December 2019 until November 2024 and serves as its Director since April 2016. He has successfully Partnered with entrepreneurs across a range of company types and stages, from early-stage metabolic companies to commercial-stage dermatology companies. He has also been active in company formation around both early- and later-stage assets. He has led and served as Director for many successful Frazier Life Sciences investments, including ARMO (acquired by Eli Lilly), Ignyta (acquired by Roche), Silvergate Pharmaceuticals (acquired by CutisPharma), Tobira Therapeutics (acquired by Allergan), Marcadia (acquired by Roche), Calixa (acquired by Cubist), Cerexa (acquired by Forest), PreCision Dermatology (acquired by Valeant), MedPointe (acquired by Meda) and Collegium. He serves on the boards of HilleVax, Inc since September 2021 and Scout Bio. He is also a Board observer for Aspen Neuroscience. He serves as Chairman of the Board at Alpha-9 Theranostics, Inc. Mr. Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December 2023 and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck & Co., Inc). from October 2014 to May 2022. He serves on the boards of Directors of Amunix and served as Director of ScoutBio until February 2025. He focuses on Early Stage and Growth Equity, Life Science, Biotechnology and Biopharma. He founded QuatRx Pharmaceuticals Company in late 2000 and Trubion. Prior to joining Frazier Management, L.L.C. he has helped to develop McKinsey and Co.'s West Coast biotechnology consulting practice after starting his career working with large pharmaceutical clients on the East Coast. At McKinsey he led projects involving mergers and acquisitions, product launches, sales force optimization, corporate Partnering and research prioritization. Prior to joining McKinsey, Mr. Heron was with Cetus Corporation. He has been a Director of QuatRx Pharmaceuticals Company since November 2000 and Zavante Therapeutics, Inc. since March 30, 2016. He served as an Independent Director of Passage Bio, Inc. since September 2018 until May 27, 2021. He served as a Director of Vaxcyte, Inc. since March 21, 2017, until September 2021. He has been an Independent Director of Mirum Pharmaceuticals, Inc. since November 2018. He has been a Director of VentiRx Pharmaceuticals, Inc. since March 6, 2007. He has been a Director at Trubion Pharmaceuticals since November 20, 2002. He serves as a Director of Genecraft GmbH and Kalidex Pharmaceuticals, Inc. He served as a Director of Iterum Therapeutics plc, from August 2015 to March 2021. He served as a Director of Collegium Pharmaceuticals, Inc. from July 2008 to June 2016. He served as Director of Tobira Therapeutics from March 2007 to November 1, 2016. He worked with Massachusetts General Hospital in evaluating spin-off opportunities. Mr. Heron holds an MBA from Harvard University, Harvard Business School and was a Phi Beta Kappa graduate and a MoreHead Scholar at the University of North Carolina at Chapel Hill with a BA in Political Science.ar.
Positions
- Company NameMBX Biosciences, Inc.Stock CodeMBXPositionIndependent DirectorColleagues
- SLSteven L. HoerterExecutive Chairperson, CEO & President
- SASalomon AzoulayChief Medical Officer
- JWJohn W. SmitherChief Financial Officer
- PDPete De SpainSenior Vice President of Investor Relations & Corporate Communications
- JHJeffrey HeldChief Legal Officer
- OHOra Hirsch PescovitzIndependent Director
- LDLaurie D. StelzerIndependent Director
- ETEdward T. MathersIndependent Director
